SIDRE: Symptomatic Improvement of Dry Eye Study

References

• LempMABaudouinCBaumJThe definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Work ShopOcul Surf200752759217508116
   PubMed Web of Science ®Google Scholar
• MiljanovićBDanaRSullivanDASchaumbergDAImpact of dry eye syndrome on vision-related quality of lifeAm J Ophthalmol2007143340941517317388
   PubMed Web of Science ®Google Scholar
• SmithJAAlbeitzJBegleyCCafferyBNicholsKSchaumbergDThe epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007)Ocul Surf2007529310717508117
   PubMed Web of Science ®Google Scholar
• StevensonWChauhanSKDanaRDry eye disease: an immune-mediated ocular surface disorderArch Ophthalmol201213019010022232476
   PubMedGoogle Scholar
• TsengSCA practical treatment algorithm for managing ocular surface and tear disordersCornea201130Suppl 1S8S1421912234
   PubMed Web of Science ®Google Scholar
• GumusKCavanaghDHThe role of inflammation and antiinflammation therapies in keratoconjunctivitis siccaClin Ophthalmol20093576719668545
   PubMedGoogle Scholar
• ShayEKheirkhahALiangLShehaHGregoryDGTsengSCAmniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysisSurv Ophthalmol200954668669619699503
   PubMed Web of Science ®Google Scholar
• LempMAManagement of dry eye diseaseAm J Manag Care2008143 SupplS88S10118452372
   PubMedGoogle Scholar
• PflugfelderSCSolomonASternMEThe diagnosis and management of dry eye: a twenty-five-year reviewCornea200019564464911009316
   PubMed Web of Science ®Google Scholar
• BavingerJCDeLossKMianSIScleral lens use in dry eye syndromeCurr Opin Ophthalmol201526431932426058032
   PubMed Web of Science ®Google Scholar
• GalorAZhengDDArheartKLDry eye medication use and expenditures: data from the medical expenditure panel survey 2001 to 2006Cornea201231121403140722895158
   PubMed Web of Science ®Google Scholar
• PflugfelderSCPrevalence, burden, and pharmacoeconomics of dry eye diseaseAm J Manag Care2008143 SupplS102S10618452369
   PubMedGoogle Scholar
• KymionisGDBouzoukisDIDiakonisVFSiganosCTreatment of chronic dry eye: focus on cyclosporineClin Ophthalmol20082482983619668437
   PubMedGoogle Scholar
• SheppardJDScoperSVSamudreSTopical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye diseaseJ Ocul Pharmacol Ther2011271232721133792
   PubMed Web of Science ®Google Scholar
• SchiffmanRMChristiansonMDJacobsenGHirschJDReisBLReliability and validity of the Ocular Surface Disease IndexArch Ophthalmol2000118561562110815152
   PubMedGoogle Scholar
• EcoiffierTEl AnnanJRashidSSchaumbergDDanaRModulation of integrin alpha4beta1 (VLA-4) in dry eye diseaseArch Ophthalmol2008126121695169919064851
   PubMedGoogle Scholar
• SheppardJDTorkildsenGLLonsdaleJDOPUS-1 Study GroupLifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 studyOphthalmology2014121247548324289915
   PubMed Web of Science ®Google Scholar
• MurphyCJBentleyEMillerPEThe pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogsInvest Ophthalmol Vis Sci20115263174318021330663
   PubMed Web of Science ®Google Scholar
• SembaCPTorkildsenGLLonsdaleJDA phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eyeAm J Ophthalmol2012153610501060.e122330307
   PubMed Web of Science ®Google Scholar
• BrewittHSistaniFDry eye disease: the scale of the problemSurv Ophthalmol200145Suppl 2S199S20211587143
   PubMed Web of Science ®Google Scholar
• ChotikavanichSde PaivaCSLi deQProduction and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndromeInvest Ophthalmol Vis Sci20095073203320919255163
   PubMed Web of Science ®Google Scholar
• SunYZhangRGadekTRO’NeillCAPearlmanECorneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118)J Ocul Pharmacol Ther201329439540223215542
   PubMed Web of Science ®Google Scholar
• EdwardsJCWilkinsonLSSpeightPIsenbergDAVascular cell adhesion molecule 1 and alpha 4 and beta 1 integrins in lymphocyte aggregates in Sjögren’s syndrome and rheumatoid arthritisAnn Rheum Dis199352118068117504438
   PubMed Web of Science ®Google Scholar
• GaoJMorganGTieuDICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjogrens syndrome-like MRL/lpr miceExp Eye Res200478482383515037117
   PubMed Web of Science ®Google Scholar
• AronniSCortesMSacchettiMUpregulation of ICAM-1 expression in the conjunctiva of patients with chronic graft-versus-host diseaseEur J Ophthalmol2006161172316496240
   PubMed Web of Science ®Google Scholar
• SaitoITerauchiKShimutaMExpression of cell adhesion molecules in the salivary and lacrimal glands of Sjogren’s syndromeJ Clin Lab Anal1993731801878509947
   PubMed Web of Science ®Google Scholar
• MahFMilnerMYiuSDonnenfeldEConwayTMHollanderDAPERSIST: Physician’s Evaluation of Restasis (R) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective reviewClin Ophthalmol201261971197623226002
   PubMedGoogle Scholar
• GaytonJLEtiology, prevalence, and treatment of dry eye diseaseClin Ophthalmol2009340541219688028
   PubMedGoogle Scholar
• SallKNCohenSMChristensenMTSteinJMAn evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eyeEye Contact Lens2006321212616415689
   PubMedGoogle Scholar
• RajpalRKDigbyDD’AversaGMahFHollanderDAConwayTIntraocular pressure elevations with loteprednol etabonate: a retrospective chart reviewJ Ocul Pharmacol Ther201127330530821574815
   PubMed Web of Science ®Google Scholar